A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy
The main purpose of this study is to measure the long-term safety and tolerability of efgartigimod PH20 SC in adult participants with Idiopathic Inflammatory Myopathy (IIM) who previously participated in ARGX-113-2007.
The study consists of a treatment period where participants will receive efgartigimod PH20 SC for up to 51 months. The treatment period will be followed by a treatment-free safety follow-up period of 56 days.
Inclusion Criteria:
Exclusion Criteria:
San Francisco, California 94143, United States
Tampa, Florida 33616, United States
Chapel Hill, North Carolina 27514, United States
Austin, Texas 78759, United States
Nanjing, Jingsu 210000, China
Chengdu, 610072, China
Shanghai, 200001, China
Zhengzhou, 450052, China
Paris, 75013, France
Berlin, 10117, Germany
Athens, 115 27, Greece
Milan, 20132, Italy
Lima, 27, Peru
Lodz, 90-549, Poland
Szczecin, 71-252, Poland
Liverpool, L9 7AL, United Kingdom